Journal of Prostate Cancer
Open Access

Cabazitaxel

Search results for
Cabazitaxel

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Awards & Nominations
Publication Policies and Ethics
Indexed In
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • Publons
View More
Useful Links
Related Subjects
View More
Share This Page

Cabazitaxel

Cabazitaxel is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug and classified as a "taxane derivitive" and an "anti-microtubule agent." It is approved for treatment for treatment of patients with castrate resistant metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.

Nausea: feeling of need to vomit, Constipation: hardened feces , delayed passage of feces . Low-blood count: decrease in white and red blood count for temporarily, Fever: if fever is above 100.4 F consult doctor.

Related Journals of Cabazitaxel

Journal of Prostate Cancer, Journal of Cancer Science & Therapy, Dovepress, European Journal of Hospital Pharmacy, Indo American Journal of Pharmaceutical Research

Cabazitaxel

Conference Proceedings